<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara LeVarge, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nestor L Muller, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis (PVOD/PCH) are now considered the same disease. PVOD/PCH is a rare condition that represents a small subgroup of adult patients with pulmonary hypertension (PH)  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]. The terms "isolated pulmonary venous sclerosis," "obstructive disease of the pulmonary veins," and "venous form of primary pulmonary hypertension" were previously used to describe the syndrome [<a href="#rid4">4-7</a>]. Compared with pulmonary arterial hypertension (eg, idiopathic or heritable PAH), PVOD/PCH-associated PH has a grim prognosis and serious adverse effects can occur when pulmonary hypertension-specific advanced therapy is administered. Thus, the suspicion for and early identification of PVOD/PCH is critical to its management. For the purposes of this topic, the term PVOD will be used.</p><p>The epidemiology, pathogenesis, clinical features, and diagnosis of PVOD are reviewed here. The treatment of PVOD-associated PH as well as the clinical features and diagnosis of other forms of pulmonary hypertension are discussed separately. (See  <a class="medical medical_review" href="/d/html/105037.html" rel="external">"Treatment and prognosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p class="headingAnchor" id="H668288699"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) has classified pulmonary hypertension (PH) based upon etiology and mechanism into the five groups listed below  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) [<a href="#rid8">8</a>]. Pulmonary arterial hypertension (PAH) refers to group 1 PAH. Pulmonary hypertension (PH) refers to any of group 2 through group 5 PH, and is also used when referring to all five groups collectively.</p><p class="bulletIndent1"><span class="glyph">●</span>Group 1 – PAH (PVOD is a subgroup of this type of PAH)</p><p class="bulletIndent1"><span class="glyph">●</span>Group 2 – PH due to left heart disease</p><p class="bulletIndent1"><span class="glyph">●</span>Group 3 – PH due to chronic lung disease and/or hypoxemia</p><p class="bulletIndent1"><span class="glyph">●</span>Group 4 – Chronic thromboembolic pulmonary hypertension (CTEPH)</p><p class="bulletIndent1"><span class="glyph">●</span>Group 5 – PH due to unclear multifactorial mechanisms</p><p></p><p>PVOD and PCH are classified as a subgroup of PAH since they share diagnostic hemodynamic similarities with PAH (see <a class="local">'Right heart catheterization'</a> below). However, while PAH causes pre-capillary pulmonary hypertension (ie, pulmonary "arteriolar" hypertension, which overall includes those in groups 1, 3, 4, and some patients in group 5 PH), PVOD and PCH are forms of mixed pre-capillary, capillary, and post-capillary pulmonary hypertension (ie, pulmonary "venous" hypertension) similar in this manner to patients with group 2 PH  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The true incidence of PVOD is unknown, primarily because many cases are probably misclassified as idiopathic PAH (IPAH) or chronic thromboembolic pulmonary arterial hypertension (CTEPH)  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) [<a href="#rid9">9,10</a>]. However, estimates from a pooled analysis of seven case series (465 patients) suggest that PVOD accounts for 10 percent of cases of PAH (range 5 to 25 percent) [<a href="#rid11">11-18</a>]. Thus, the annual incidence of PVOD is estimated to be 0.1 to 0.2 cases per million persons in the general population [<a href="#rid19">19</a>].</p><p>Many cases of PVOD are detected in children and young adults. More recently, however, a bimodal age distribution has been demonstrated, with a separate population affected in later life (ages 60 to 80) [<a href="#rid20">20</a>]. Age at diagnosis has ranged from eight weeks to the ninth decade of life [<a href="#rid21">21</a>].</p><p>Unlike classic IPAH, which has a female preponderance, PVOD affects males and females equally [<a href="#rid2">2,22,23</a>]. However, among non-familial cases of PVOD, another series suggested a male predominance in the condition [<a href="#rid20">20</a>].</p><p>The epidemiology of other forms of pulmonary hypertension is discussed separately.</p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS AND RISK FACTORS</span><span class="headingEndMark"> — </span>Most cases of PVOD are idiopathic. The pathogenesis is unknown and likely multifactorial. It has been postulated that PVOD may represent a common aberrant response to an inciting event of endothelial injury that leads to widespread fibrosis of pulmonary venules [<a href="#rid24">24</a>]. A familial form of PVOD and several risk factors have been reported, the details of which are discussed in the sections below. (See <a class="local">'Genetic factors'</a> below and <a class="local">'Drugs and toxins'</a> below and <a class="local">'Autoimmune disorders'</a> below and <a class="local">'Miscellaneous'</a> below.)</p><p>The pathogenesis of other forms of pulmonary hypertension (PH) is provided separately. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Pathogenetic mechanisms'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Families with multiple members affected by PVOD have been identified, suggesting a genetic basis for some with this disease [<a href="#rid7">7,17,25-27</a>]. The age at which the disease presented in such families has ranged from eight weeks to age 50 [<a href="#rid27">27</a>].</p><p>Genetic mutations of the following have been identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Eukaryotic translation initiation factor 2-alpha kinase (<em>EIF2AK4</em>) gene – One study of 13 families with PVOD detected recessive and biallelic mutations in the <em>EIF2AK4</em> gene [<a href="#rid27">27</a>]. Biallelic mutations have also been described in 25 percent sporadic cases of PVOD [<a href="#rid27">27,28</a>]. In a registry of patients with suspected PVOD, those with biallelic mutations of <em>EIF2AK4</em> presented at a younger age but disease severity was similar to those without mutations [<a href="#rid29">29</a>]. Two brothers with PCH (thought to be a variant of PVOD), were also identified to have biallelic mutations in <em>EIF2AK4</em>, as were 2 out of 10 patients with sporadic PCH [<a href="#rid30">30</a>]. This kinase, <em>EIF2AK4</em> (also called <em>GCN2</em>), phosphorylates the protein, EIF2, to down regulate protein synthesis necessary for cell growth and replication. Thus, mutations potentially result in uncontrolled cell growth. We generally test patients with suspected PVOD for mutations in this gene, particularly among patients &lt;40 years of age. (See <a class="local">'Evaluation and approach to clinical diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone morphogenetic protein receptor type II (<em>BMPR2</em>) – Mutations in several loci of the <em>BMPR2</em> gene have been reported in patients with PVOD [<a href="#rid2">2,31,32</a>]. <em>BMPR2</em> mutations are responsible for up to one-half of all cases of familial pulmonary arterial hypertension (PAH), and as many as 25 percent of cases of nonfamilial PAH. The true incidence in PVOD is unknown but mutations appear to be significantly less common than in those with typical PAH (ie, pre-capillary PAH) [<a href="#rid20">20</a>]. The bone morphogenetic protein family of proteins is related to TGF-beta and consists of at least 10 peptides that are produced by many different cells and have multiple actions on growth and development. Centers with expertise in PH test patients with a family history for mutations in this gene, regardless of the suspicion for PVOD, the details of which are provided separately. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Genetic mutations'</a>.)</p><p></p><p>While the occurrence of a rare disease in two members of the same family may indicate an exclusively genetic component, common exposures to food, drugs, environmental agents, or infectious diseases could also play a role.</p><p class="headingAnchor" id="H197820318"><span class="h2">Epigenetic or immunomodulatory factors</span><span class="headingEndMark"> — </span>Epigenetic factors may also be important in the pathogenesis of PVOD. Granulysin (<em>GNLY</em>) is a proinflammatory molecule present in cytotoxic granules of T cells that has been implicated in many disease processes. One study reported reduction in the demethylation of the <em>GNLY</em> gene in the lungs and blood of patients with PVOD compared with idiopathic or heritable PAH patients and normal controls who do not have PAH [<a href="#rid33">33</a>]. This was associated with a decrease in circulating cytotoxic and natural killer T cells and an increase of natural killer cells.</p><p class="headingAnchor" id="H7"><span class="h2">Drugs and toxins</span><span class="headingEndMark"> — </span>Exposures to chemotherapeutic agents are more commonly encountered in patients with PVOD than in patients with typical group 1 PAH (ie, pre-capillary PAH)  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). In contrast, anorexigen exposure, which is a risk factor for the development of group 1 PAH, is rare in PVOD.</p><p>The following drugs and toxins have been reported to be associated with PVOD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapeutic regimens</strong> – Recognition of hepatic veno-occlusive disease (HVOD) as a complication of antineoplastic chemotherapy was followed by reports of a similar association between PVOD and a variety of chemotherapy regimens [<a href="#rid34">34</a>]. A definitive association with specific medications has been difficult to identify because many patients are exposed to multiple chemotherapy regimens over several years. However, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> (also known as Mitomycin-C), <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a> (BCNU), <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, mechlorethamine (no longer systemically available), <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> are thought to confer the greatest risk [<a href="#rid34">34-39</a>]. PVOD may be a consequence of the toxic metabolites of antineoplastic chemotherapy damaging pulmonary venule endothelium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemicals</strong> – Chemical exposures also contribute to the development of PVOD. In a case-control study of 33 patients with PVOD, occupational exposure to organic solvents (especially trichlorethylene) was associated with an eight-fold risk in the development of PVOD [<a href="#rid20">20</a>]. In a separate case report, a 14 year-old boy who had a two-year history of ingesting and sniffing a powdered cleaning product developed PVOD [<a href="#rid40">40</a>]. The cleaning product contained silica, soda ash, dodecyl benzyl sulfonate, and trichloro-s-triazinetriome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cigarette smoking</strong> – As compared with patients with other forms of PAH (eg, pre-capillary PAH), patients with PVOD have greater previous smoking exposure [<a href="#rid2">2</a>].</p><p></p><p>Drugs that are risk factors for PAH (eg, cocaine and anorectic agents such as <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a>) or HVOD (eg, bush teas containing pyrrolizidine alkaloids) have not been associated with PVOD [<a href="#rid26">26,41-43</a>]. Toxins associated with the development of PAH and HVOD are discussed separately. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Drugs and toxins'</a> and  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p class="headingAnchor" id="H74965762"><span class="h2">Hematopoietic stem cell transplant</span><span class="headingEndMark"> — </span>PVOD appears to be more common after hematopoietic stem cell transplantation (allogeneic or autologous) than following routine cytoreductive chemotherapy, but this impression is anecdotal and has not been confirmed with empirical evidence [<a href="#rid24">24,44-47</a>]. An autopsy series of 35 patients who died more than one year following allogenic stem cell transplant revealed PVOD in 12 patients (34.3 percent); as only one subject was clinically diagnosed prior to death, it is not clear if the diagnosis was clinically significant in all cases [<a href="#rid48">48</a>]. Proposed mechanisms include chemotherapy- or radiation-induced injury as well as factors related to the transplant itself. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary veno-occlusive disease'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Autoimmune disorders</span><span class="headingEndMark"> — </span>Most patients with PVOD lack features of systemic autoimmune disease. However, case reports have described PVOD in association with the following autoimmune disorders [<a href="#rid49">49-66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis and Felty syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus</p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Langerhans cell histiocytosis</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic sclerosis</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed connective tissue disease</p><p class="bulletIndent1"><span class="glyph">●</span>CREST syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic active hepatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Hashimoto's thyroiditis</p><p class="bulletIndent1"><span class="glyph">●</span>Celiac disease</p><p class="bulletIndent1"><span class="glyph">●</span>Focal or systemic granulomatous venulitis</p><p class="bulletIndent1"><span class="glyph">●</span>Sjögren's disease</p><p class="bulletIndent1"><span class="glyph">●</span>Antisynthetase syndrome</p><p></p><p>Although supportive of a possible immunologic basis for PVOD, there has been insufficient evidence to support a clear mechanism underlying the development of PVOD in patients with autoimmune disorders. In addition, the presence of connective tissue or autoimmune disorders does not distinguish PAH from PVOD as many of these disorders are encountered in typical PAH (ie, pre-capillary PAH). In patients with PAH and systemic sclerosis, where PVOD is of particular concern, imaging and pathologic features of PVOD occur frequently, although data regarding the clinical significance on prognosis and treatment response has been mixed [<a href="#rid61">61,67,68</a>].</p><p class="headingAnchor" id="H450640521"><span class="h2">Miscellaneous</span><span class="headingEndMark"> — </span>Several additional mechanisms have been proposed but are not likely to be causative:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Previous infection is a frequently cited risk factor for PVOD but there is insufficient evidence to support it as a plausible cause [<a href="#rid69">69,70</a>]. Observations that have suggested infection as a risk factor for PVOD include: an influenza-like illness often precedes the development of PVOD, serological tests performed around the time of diagnosis have suggested recent infection with Toxoplasma gondii or measles [<a href="#rid4">4,5,71</a>], features suggestive of Epstein-Barr or cytomegalovirus infection (eg, lymphadenopathy, fever, and erythrophagocytosis) have been reported around the time of diagnosis [<a href="#rid72">72</a>], and two cases have been reported in association with human immunodeficiency virus (HIV) infection [<a href="#rid73">73,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombotic diathesis</strong> – A number of researchers have theorized that a thrombotic diathesis (ie, a predisposition toward thrombosis or a defect in fibrinolysis) may play a role in the pathogenesis of PVOD. The theory is supported by early reports of increased platelet adhesiveness in patients with PVOD [<a href="#rid4">4,75</a>], as well as cases in which PVOD occurred in conjunction with risk factors for hypercoagulability (eg, oral contraceptive use, pregnancy, myeloproliferative disorders) [<a href="#rid76">76-79</a>]. Arguing against the theory, documented venous or arterial thrombi are rare in the extrapulmonary circulation of patients with PVOD and many patients do not have evidence of pulmonary venous thrombi on histopathologic examination [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital</strong> – Rare cases of PVOD have been described in infants with hypoplastic left heart syndrome, scimitar syndrome, and partial anomalous pulmonary vein connection [<a href="#rid81">81-84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal</strong> – PVOD has been reported in patients taking oral contraceptives and during pregnancy which is considered by most experts as an incidental association only, although a causative role cannot be ruled out [<a href="#rid76">76-78</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">EVALUATION AND APPROACH TO CLINICAL DIAGNOSIS</span></p><p class="headingAnchor" id="H162215674"><span class="h2">Overview</span><span class="headingEndMark"> — </span>There has been a paradigm shift in the diagnosis of patients with PVOD. In the past, many patients required a surgical lung biopsy for definitive histopathologic diagnosis. However, most experts now believe that a clinical diagnosis of PVOD can be made in most patients following an integrated assessment for pulmonary hypertension using a constellation of clinical, computed tomographic (contrast-enhanced CT), physiologic, and hemodynamic findings  (<a class="graphic graphic_table graphicRef105806" href="/d/graphic/105806.html" rel="external">table 3</a>) [<a href="#rid85">85-87</a>]. We and other experts prefer this noninvasive approach to the diagnosis since the risk of biopsy in patients with pulmonary vasculopathy is considerably high (hemorrhage, hemodynamic collapse).</p><p>During the evaluation of patients for pulmonary hypertension (PH), PVOD should be suspected in those with manifestations of pulmonary arterial hypertension who have evidence of pulmonary venous congestion in the absence of left-sided heart disease. Importantly, the following should be kept in mind:</p><p class="bulletIndent1"><span class="glyph">●</span>With the exception of patients with biallelic mutations in the <em>EIF2AK4</em> gene, the diagnosis of PVOD cannot be made unless right heart catheterization has demonstrated findings consistent with pulmonary arterial hypertension (PAH; ie, an elevated mean pulmonary artery pressure &gt;20 mmHg and a normal pulmonary artery occlusion pressure ≤15 mmHg, and an elevated pulmonary vascular resistance ≥3 Wood Units). The major diagnostic challenge for clinicians is to distinguish PVOD-associated PH from other forms of group 1 PAH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) since there is considerable clinical and hemodynamic overlap between these two entities. (See <a class="local">'Hemodynamic findings of PAH'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is the interpretation of additional clinical findings in this context, that a confident clinical diagnosis of PVOD is generally made:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Common supportive features include the CT findings of pulmonary capillary hypertension (eg, septal thickening, diffuse ground glass opacities and lymphadenopathy). These and other supportive radiographic findings are discussed below. (See <a class="local">'Venous congestion on chest imaging'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physiologic abnormalities of low diffusion and poor oxygenation provide additional evidence to support the diagnosis. However, these features are generally not specific. (See <a class="local">'Low diffusing capacity and poor oxygenation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identification of biallelic mutations in the <em>EIF2AK4</em> gene is sufficient to establish or confirm the diagnosis [<a href="#rid88">88</a>]. (See <a class="local">'Family history or EIF2AK4 mutation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of PVOD is highly suggested when pulmonary edema develops following vasoreactivity testing or PAH-specific advanced therapy.</p><p></p><p>Surgical lung biopsy is rarely performed, and histologic confirmation may not be obtained until examination of an explanted lung or at autopsy. (See <a class="local">'Histopathology'</a> below and <a class="local">'Lung biopsy'</a> below.)</p><p>The evaluation of patients with suspected PH is provided separately  (<a class="graphic graphic_algorithm graphicRef72553" href="/d/graphic/72553.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H5527924"><span class="h2">Clinical manifestations of pulmonary hypertension</span><span class="headingEndMark"> — </span>Most patients with PVOD present with prominent symptoms of pulmonary hypertension (PH), none of which are specific for PVOD [<a href="#rid2">2,89-93</a>]. Data that describe the clinical manifestations of PVOD are discussed in this section, while a detailed discussion of the clinical presentation of PH is provided separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a>.)</p><p>Two of the largest case series of patients with PVOD report a similar profile of symptoms to that in patients with PH including the following [<a href="#rid2">2,90</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea on exertion and lethargy (&gt;95 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of right heart failure (55 percent; eg, leg edema, right upper quadrant pain secondary to hepatic congestion)</p><p class="bulletIndent1"><span class="glyph">●</span>Exertional syncope (45 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic cough (36 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Atypical chest pain (18 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Orthopnea (18 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoptysis (8 percent)</p><p></p><p>Two-thirds of patients presented with World Health Organization (WHO) class III, with fewer cases presenting with functional class II (17 percent) or IV (20 percent) [<a href="#rid2">2</a>]. While one case series reported a higher incidence of patients presenting with hemoptysis in those with PVOD compared with patients who have other forms of PAH (8 versus 4 percent)  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), this was not significant. When it occurs, hemoptysis is typically minimal and rarely massive or life threatening, although diffuse alveolar hemorrhage and sudden death are uncommonly described presentations of PVOD.</p><p>Exposure to toxins or the presence of conditions classically associated with PVOD (eg, <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, trichloroethylene, systemic sclerosis, hematopoietic stem cell transplantation) should raise the suspicion for PVOD. (See <a class="local">'Drugs and toxins'</a> above and <a class="local">'Hematopoietic stem cell transplant'</a> above and <a class="local">'Autoimmune disorders'</a> above.)</p><p>The signs of PVOD are generally those of progressive PH, including cyanosis, a loud pulmonic component of the second heart sound, a split-second heart sound, right-sided cardiac murmurs (eg, tricuspid regurgitation), a third or fourth heart sound (ie, gallop), a left parasternal heave, a downward subxiphoid thrust, a pulmonary artery tap, elevated jugular venous pressure, an enlarged liver, and peripheral edema. Auscultatory crackles may occur in patients who have prominent chronic pulmonary infiltrates and decreased breath sounds with dullness to percussion may exist in patients with pleural effusions.</p><p>Since these symptoms are shared with PAH and sometimes mistaken for a respiratory infection, the initial suspicion for PVOD is frequently low, resulting in a delayed diagnosis. (See <a class="local">'Diagnostic delay'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h2">Venous congestion on chest imaging</span><span class="headingEndMark"> — </span>Similar to patients with other forms of PAH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), patients with PVOD commonly have imaging features of pulmonary hypertension including enlargement of central pulmonary arteries and the right ventricle  (<a class="graphic graphic_diagnosticimage graphicRef69446" href="/d/graphic/69446.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef72063" href="/d/graphic/72063.html" rel="external">image 2</a>). Importantly, many patients with PVOD additionally have findings of capillary congestion and lymphadenopathy, but with a normal-sized left atrium and normal-sized major pulmonary veins (66 to 100 percent).</p><p>The triad of diffuse ground glass opacification (particularly centrilobular distribution), septal thickening, and mediastinal lymphadenopathy in patients with PAH, is thought to be highly suggestive of PVOD [<a href="#rid2">2,91</a>]. One study reported a diagnostic sensitivity and specificity of over 80 and 67 percent, respectively, when one or more of these findings were present [<a href="#rid91">91</a>]. In this study, CT scans of 15 patients with histologically confirmed PVOD were compared with those from pathologically confirmed idiopathic PAH. Ground-glass opacities were significantly more frequent in PVOD (87 versus 33 percent) as were subpleural septal lines (93 versus 13 percent), and lymphadenopathy (80 versus 0 percent). In a review of the CT manifestations in 25 consecutive patients with PVOD, all had at least one of the three findings (ground glass opacities, septal lines, lymphadenopathy) and 92 percent of patients had at least two of the findings, the most common one being septal thickening seen in 23 (92 percent) of the 25 patients [<a href="#rid94">94</a>].</p><p>However, clinicians should be aware many of these features are non-specific, and their absence does not exclude a diagnosis of PVOD.</p><p>The presence of venous congestion and lymphadenopathy with a normal-sized left atrium and normal-sized major pulmonary veins are features that may help distinguish PH due to PVOD from other causes of post-capillary PH, namely that due to left-sided heart disease (ie, group 2 PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>)). These features are likely due to chronic pulmonary capillary hypertension, transudation of fluid into the interstitium, and enlargement of pulmonary lymphatic channels. However, in general, these features are not highly specific since they may be seen in many other pulmonary disorders including pulmonary hemorrhage, infarction, infection, and sarcoidosis; thus their presence or absence neither confirms nor precludes a diagnosis of PVOD.</p><p class="headingAnchor" id="H450641310"><span class="h3">Chest radiography</span><span class="headingEndMark"> — </span>Similar to patients with other forms of PAH, chest radiographs may demonstrate enlargement of the central pulmonary arteries (ie, signs of pulmonary arterial hypertension). In contrast, additional radiographic signs of venous congestion including scattered patchy parenchymal opacities, Kerley B lines, and lymphadenopathy with a normal left atrium may be suggestive of PVOD  (<a class="graphic graphic_diagnosticimage graphicRef53287" href="/d/graphic/53287.html" rel="external">image 3</a>) [<a href="#rid23">23,95-98</a>]. Pleural effusion (from elevated pulmonary capillary and visceral pleural capillary hydrostatic pressure) is a frequently cited chest radiograph finding in patients with PVOD [<a href="#rid2">2,61,90,95,98</a>]. While pleural effusions were thought to be more frequent in patients with PVOD than typical PAH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), studies using CT do not support this distinction [<a href="#rid2">2,91,99-101</a>].</p><p>Details regarding the utility of chest radiography in the evaluation of patients with suspected PH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Imaging'</a>.)</p><p class="headingAnchor" id="H450641304"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>CT scans usually show features of venous congestion similar to those seen on chest radiography but with improved resolution  (<a class="graphic graphic_diagnosticimage graphicRef105805" href="/d/graphic/105805.html" rel="external">image 4</a>). Retrospective reports suggest that over two-thirds of patients with PVOD have evidence of CT abnormalities (ranges from 66 to 100 percent) with some reports suggesting that the diagnostic sensitivity of the classic PVOD triad of patchy ground glass opacities, septal lines, and mediastinal adenopathy is greater than 80 percent. (See <a class="local">'Venous congestion on chest imaging'</a> above.)</p><p>CT findings include the following [<a href="#rid91">91,99,101-107</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of PH itself (eg, central pulmonary artery enlargement, right ventricle dilation or hypertrophy, intraventricular septal bowing)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of post capillary venous congestion including smooth septal thickening, diffuse or mosaic ground glass opacities, multiple small nodules, pleural effusions, pericardial effusions, or areas of alveolar consolidation (often in a centrilobular distribution)  (<a class="graphic graphic_diagnosticimage graphicRef71206" href="/d/graphic/71206.html" rel="external">image 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal lymphadenopathy, which may be a consequence of venolymphatic shunts and circulating angiogenic factors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal-sized pulmonary veins and left atrium</p><p></p><p>One study has reported that centrilobular ground glass opacities tend to be smaller in patients with PVOD than in those with PCH (2.5 mm versus 5.6 mm), although the diagnostic value of this observation is unclear [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H450641316"><span class="h3">Ventilation perfusion scanning</span><span class="headingEndMark"> — </span>Ventilation-perfusion (V/Q) images are frequently performed in the evaluation of patients with suspected PAH. However, for patients with suspected PVOD, they are of limited diagnostic value because they are often normal or lead to misdiagnosis [<a href="#rid98">98,108-110</a>]. As an example, a small proportion of patients with PVOD (approximately 7 percent) have normal ventilation with focal areas of hypoperfusion (ie, unmatched perfusion defects), which are classically associated with chronic thromboembolic pulmonary hypertension (CTEPH). Thus, the finding of an unmatched defect in PVOD may lead to a misdiagnosis of CTEPH. (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension", section on 'Features specific to thromboembolism'</a>.)</p><p class="headingAnchor" id="H162212875"><span class="h2">Low diffusing capacity and poor oxygenation</span><span class="headingEndMark"> — </span>A severely reduced single breath diffusing capacity for carbon monoxide (DLCO), partial pressure for arterial oxygen (PaO<sub>2</sub>), and oxygen saturation nadir on six-minute walk testing (6MWT) should raise the suspicion for PVOD. While the optimal cutoff values are not standardized, we consider a DLCO &lt;55 percent predicted, a PaO<sub>2</sub> &lt;65 mmHg (8.7 kPa), and O<sub>2</sub> saturation (&lt;85 percent) during 6MWT as severe. However, although suggestive of PVOD, clinicians should be aware that these features are not pathognomonic and can be found in other etiologies.</p><p>Best illustrating this feature as suggestive of PVOD is a retrospective analysis that compared 24 patients with histologically proven PVOD with 24 patients who had IPAH [<a href="#rid2">2</a>]. Patients with PVOD had lower DLCO (52 versus 70 percent predicted), PaO<sub>2</sub> (61 versus 75 mmHg) and nadir on 6MWT (80 versus 87 percent).</p><p class="headingAnchor" id="H203580"><span class="h3">Pulmonary function tests</span><span class="headingEndMark"> — </span>Pulmonary function testing (PFTs) are indicated during the evaluation of patients with suspected PH. PFT findings in patients with PVOD include the following [<a href="#rid2">2,85,90,97</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Spirometry – In patients with PVOD spirometric values are frequently normal or show a mild restrictive pattern but obstructive ventilatory deficits have also been described.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung volumes – Lung volumes are typically in the normal or slightly reduced range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DLCO – The single breath DLCO is typically reduced.</p><p></p><p>Notably, a reduced DLCO can be found in many other conditions as well as in severe PAH. Conversely, a normal or mildly reduced value does not exclude the diagnosis and it may be falsely overestimated when occult alveolar hemorrhage occurs as a complication of PVOD. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a> and  <a class="medical medical_review" href="/d/html/6971.html" rel="external">"Selecting reference values for pulmonary function tests"</a>.)</p><p class="headingAnchor" id="H203751"><span class="h3">Arterial blood gas</span><span class="headingEndMark"> — </span>The finding of severe hypoxemia and low nadir on 6MWT is also nonspecific and most experts consider that, although suggestive of PVOD, such parameters of oxygenation do not definitively distinguish between these etiologies. (See  <a class="medical medical_review" href="/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a> and  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults", section on 'Six-minute walk test'</a>.)</p><p class="headingAnchor" id="H1174611225"><span class="h3">Cardiopulmonary exercise testing</span><span class="headingEndMark"> — </span>Data regarding cardiopulmonary exercise testing (CPET) utility in suspected PVOD are still limited and suspicious cutoff values have not yet been established. Nonetheless, some findings in CPET may be helpful. CPET can objectively measure exercise performance and provide insight into etiology of limitation. As compared with patients with other forms of PAH, those with PVOD demonstrate lower peak oxygen uptake (VO<sub>2</sub>), lower resting and exercise oxygen saturations, and more ventilatory inefficiency with increased ratio of minute ventilation to carbon dioxide production (VE/VCO<sub>2</sub>) and lower end-tidal carbon dioxide during exercise [<a href="#rid111">111,112</a>].</p><p class="headingAnchor" id="H162212450"><span class="h2">Hemodynamic findings of PAH</span></p><p class="headingAnchor" id="H12"><span class="h3">Right heart catheterization</span><span class="headingEndMark"> — </span>A diagnosis of PVOD cannot be inferred until a diagnosis of pulmonary hypertension is made on right heart catheterization (RHC). Patients with PVOD have the typical hemodynamic features of PAH (elevated mean pulmonary artery pressure [&gt;20 mmHg] and a normal pulmonary artery wedge pressure [pawp; ≤15 mmHg]; occasionally, the pawp is a little elevated), and a pulmonary vascular resistance ≥3 Woods units  (<a class="graphic graphic_table graphicRef70326" href="/d/graphic/70326.html" rel="external">table 4</a>) [<a href="#rid2">2,90</a>]. It is the pre-capillary hemodynamic pattern on RHC (elevated mean pulmonary arterial pressure [mPAP] and normal pawp) together with similar symptomatology that lead to the misdiagnosis of PVOD as typical PAH. Details regarding RHC and findings in PAH are discussed separately  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'</a> and  <a class="medical medical_review" href="/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a> and  <a class="medical medical_review" href="/d/html/1595.html" rel="external">"Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults"</a> and  <a class="medical medical_review" href="/d/html/1658.html" rel="external">"Pulmonary artery catheters: Insertion technique in adults"</a>.)</p><p>The pre-capillary pattern on RHC may appear somewhat discrepant with the post-capillary pathology in PVOD. However, wedging of the balloon-tipped vascular catheter creates a static column of blood between the transducer and the left atrium so that pawp reflects the left atrial pressure; while this is typically elevated in patients with post-capillary pulmonary hypertension from left-sided heart failure, left atrial and large pulmonary venous pressures remain normal in PVOD [<a href="#rid113">113,114</a>].</p><p>Several findings during RHC may help support the presence of PVOD as an etiology for PAH:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical pawp tracing during flushing</strong> – Reliable occlusion pressure ("wedge") tracings can be difficult to obtain in patients with PVOD and they can have an unusual appearance during flushing. To document successful wedging of the catheter, an oxygen tension similar to arterial blood may need to be demonstrated using blood slowly aspirated from the distal port of the pulmonary artery catheter. Ideally, the pawp should be measured in several different locations to ensure that a given measurement is not spurious or the result of a local phenomenon. During flushing, the distal port of the wedged catheter causes the infused <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to become trapped between the catheter tip and narrowed pulmonary veins; as a result, the pressure rises disproportionately and falls extremely slowly to baseline [<a href="#rid4">4,115,116</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The development of pulmonary edema during vasoreactivity testing</strong> – A vasodilator trial (with short-acting pulmonary arterial vasodilators such as <a class="drug drug_general" data-topicid="9447" href="/d/drug information/9447.html" rel="external">inhaled nitric oxide</a>, intravenous <a class="drug drug_general" data-topicid="9411" href="/d/drug information/9411.html" rel="external">epoprostenol</a>, or <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>) is typically performed for select patients with PAH to safely predict those who may exhibit a favorable response to calcium channel blockade. The development of pulmonary edema in response to a pulmonary vasodilator is strongly suggestive of PVOD, but not pathognomonic [<a href="#rid2">2,90,117,118</a>]. Details regarding vasoreactivity testing in patients with PVOD as well as in patients with PAH are provided separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Vasoreactive patients'</a> and  <a class="medical medical_review" href="/d/html/105037.html" rel="external">"Treatment and prognosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults", section on 'Assessing vasoreactivity'</a>.)</p><p></p><p class="headingAnchor" id="H162212643"><span class="h3">Echocardiography</span><span class="headingEndMark"> — </span>Transthoracic echocardiography is a useful tool in the evaluation of patients with suspected PAH. In patients with PVOD, the major value of echocardiography is to establish the <strong>absence</strong> of significant left-sided heart disease and to evaluate the right ventricle for the typical findings of right ventricular strain due to pulmonary hypertension. (See  <a class="medical medical_review" href="/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'</a>.)</p><p class="headingAnchor" id="H162214087"><span class="h2">Family history or EIF2AK4 mutation</span><span class="headingEndMark"> — </span>In the context of patients who have hemodynamic findings consistent with PAH, patients who also have a family history of PVOD or a mutation in the <em>EIF2AK4</em> gene, are considered by most experts as likely having PVOD such that serum for mutational analysis should be sent. While hemodynamic measurements are useful in assessing progression and response to therapy in individual patients, they are not required for diagnosis in patients who are homozygous for <em>EIF2AK4</em> mutations. (See <a class="local">'Genetic factors'</a> above.)</p><p class="headingAnchor" id="H162214109"><span class="h2">Pulmonary edema from pulmonary vasodilators</span><span class="headingEndMark"> — </span>The development of acute pulmonary edema on vasoreactivity testing or during the administration of PH-specific medications is also considered by experts as highly suggestive of PVOD when the diagnosis has not been previously suspected, or supportive of the diagnosis when it is suspected. Detailed discussion of vasoreactivity testing and the risks of treating PVOD patients with PH-specific advanced therapy is provided separately. (See  <a class="medical medical_review" href="/d/html/105037.html" rel="external">"Treatment and prognosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults", section on 'Assessing vasoreactivity'</a>.)</p><p class="headingAnchor" id="H162214137"><span class="h2">Others</span><span class="headingEndMark"> — </span>Additional features that support the diagnosis of PVOD include evidence of occult hemorrhage on bronchoscopy. Laboratory tests are generally unhelpful.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoscopy and bronchoalveolar lavage</strong> – Bronchoscopy is not routinely performed in patients undergoing an evaluation for pulmonary hypertension unless there is an alternate diagnostic indication (eg, parenchymal abnormality or airway inspection for cancer in those with hemoptysis).</p><p></p><p class="bulletIndent1">Similarly, in patients with suspected or known PVOD, we do not routinely perform bronchoscopy. However, some experts routinely perform bronchoscopy in patients with suspected PVOD to identify occult alveolar hemorrhage. This latter practice is based upon one small study that identified a higher percentage of hemosiderin-laden macrophages in bronchoalveolar lavage fluid in eight patients with PVOD compared with eleven patients with idiopathic PAH (40 versus 3 percent) [<a href="#rid119">119</a>]. Given the methodological limitations of this study, it remains unclear whether or not this feature can sufficiently distinguish PVOD from other forms of PH or whether it predicts an increased risk of clinically significant hemorrhage in this population. (See  <a class="medical medical_review" href="/d/html/4398.html" rel="external">"Flexible bronchoscopy in adults: Overview"</a> and  <a class="medical medical_review" href="/d/html/4400.html" rel="external">"Flexible bronchoscopy in adults: Indications and contraindications"</a> and  <a class="medical medical_review" href="/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p></p><p class="bulletIndent1">In patients with PVOD in whom bronchoscopy is performed, airway inspection may reveal intense hyperemia of the lobar and segmental bronchi (which drain to the pulmonary veins), with vascular engorgement in the form of bright red longitudinal streaks [<a href="#rid120">120</a>]. In contrast, these findings are not present in the trachea and main bronchi, presumably because the venous drainage of central airways is into nonoccluded bronchial veins.</p><p></p><p class="bulletIndent1">Importantly, transbronchial biopsy should not be performed in patients with PVOD since it is unlikely to establish the diagnosis and it is associated with an unacceptably high complication rate (typically hemorrhage).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests and flow cytometry</strong> – Laboratory tests are generally unremarkable, although microangiopathic hemolytic anemia [<a href="#rid121">121</a>], heavy proteinuria [<a href="#rid5">5</a>], and elevations in serum IgG and IgM concentrations [<a href="#rid122">122</a>] have been described in isolated cases. While an alteration in cytotoxic T cell populations has been reported, there is no role for the routine evaluation of flow cytometry in the evaluation of patients suspected as having PVOD [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H162212108"><span class="h2">Diagnostic delay</span><span class="headingEndMark"> — </span>Delays in the diagnosis of PVOD are common since the condition is rare, the presentation is nonspecific, and not every patient presents with classic features. Many patients are initially presumed to have heart failure (due to the abnormalities on chest radiographs and CT scans), CTEPH (due to abnormalities on V/Q scans), or parenchymal lung disease, such as sarcoidosis, cystic fibrosis, or pneumoconiosis (due to chronic interstitial changes on chest radiographs) [<a href="#rid123">123</a>]. Thus, the diagnosis can be missed and is sometimes only made retrospectively at autopsy or on examination of explanted tissue. Rarely is PVOD found incidentally on lung biopsy material performed during the evaluation of interstitial lung disease. (See <a class="local">'Histopathology'</a> below.)</p><p class="headingAnchor" id="H162212114"><span class="h1">LUNG BIOPSY</span><span class="headingEndMark"> — </span>On the rare occasion that lung biopsy is pursued for definitive diagnosis (eg, in patients without classic clinical and radiologic findings who have only mild pulmonary hypertension and hypoxemia for whom biopsy risk is sufficiently low), surgical lung biopsy is preferred over transbronchial biopsy (TBBx) since the latter is typically insufficient to diagnose PVOD and the risk of uncontrolled hemorrhage is thought to be higher with TBBx. (See  <a class="medical medical_review" href="/d/html/15141.html" rel="external">"Overview of minimally invasive thoracic surgery"</a>.)</p><p class="headingAnchor" id="H63564757"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>A definitive diagnosis of PVOD requires histological examination of lung tissue. While in the past, the diagnosis was typically made on surgical lung biopsy, the diagnosis is now frequently made on clinical grounds and histological confirmation is often obtained only in explanted lung or at autopsy. (See <a class="local">'Evaluation and approach to clinical diagnosis'</a> above.)</p><p>PVOD is a fibroproliferative disease primarily affecting the small pulmonary veins with relative sparing of the larger veins. The pathologic hallmark of PVOD is extensive and diffuse occlusion of the pulmonary veins due to smooth muscle hypertrophy and collagen matrix deposition (ie, fibrous tissue). The fibrous tissue may be loose and edematous (perhaps reflecting an earlier stage of development), or dense and sclerotic (perhaps reflecting a later stage of development)  (<a class="graphic graphic_figure graphicRef52802" href="/d/graphic/52802.html" rel="external">figure 1</a>) [<a href="#rid11">11,124-126</a>]. While uncommon, luminal narrowing of the pulmonary veins from acute thrombus is also seen.</p><p>In addition, to these features, the media of the pulmonary veins may become "arterialized" with an increase in elastic fibers; when "arterialization" is extensive, these features may be mistaken for pulmonary arterial hypertension (PAH). Recanalization of completely occluded vessels occurs over time, and calcium may encrust the elastic fibers in the walls of the veins or alveoli. Intimal thickening tends to be eccentric and usually involves the venules and small veins in the interlobular septa which may help to distinguish PVOD from PAH.</p><p>Long-standing PVOD can result in the deposition of collagen fibers within lobular septae and, to a lesser degree, alveolar walls. These changes are similar to those noted in long-standing mitral stenosis [<a href="#rid127">127</a>]. Fibrosis may be sufficiently extensive that the differential diagnosis includes idiopathic pulmonary fibrosis  (<a class="graphic graphic_picture graphicRef66071" href="/d/graphic/66071.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/14870.html" rel="external">"Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"</a>.)</p><p>Pulmonary arterioles may also be involved, with moderate to severe medial hypertrophy in approximately one-half of cases [<a href="#rid128">128</a>]. Arteritis and arterial plexiform lesions, classic features of PAH, are usually absent. Such cases may represent mixed pre-capillary and post-capillary pulmonary hypertension  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 2</a>).</p><p>Alveolar capillaries may be engorged and tortuous, consistent with PCH [<a href="#rid95">95,129,130</a>]. In a retrospective cohort study, 73 percent of patients with PVOD had coexisting PCH, and venous changes were seen in most patients receiving histologic diagnosis of PCH [<a href="#rid89">89</a>]. This observation has led to the agreement among experts that, for most patients, PVOD and PCH represent the same diagnosis. PCH may be caused by PVOD; specifically, PCH may be a proliferative response to pulmonary venous hypertension. Supporting this hypothesis, PCH can complicate other diseases characterized by pulmonary venous hypertension [<a href="#rid131">131-133</a>].</p><p>Additional findings include dilated pulmonary lymphatics, dilated pleural lymphatics, and interstitial edema that is most notable in lobular septa  (<a class="graphic graphic_picture graphicRef72794" href="/d/graphic/72794.html" rel="external">picture 2</a>) [<a href="#rid80">80,107</a>]. Concomitant type II pneumocyte hyperplasia and focal lymphocytic infiltrates occur in many patients and can be extensive [<a href="#rid125">125,134</a>].</p><p>A slightly less common finding is hemosiderin in alveolar macrophages or the interstitium, thought to be due to passive congestion or occult hemorrhage. Hemorrhage may also be present, but it is difficult to distinguish blood due to disease from blood due to the biopsy procedure. Occasionally, hemosiderin or blood is sufficiently prominent that the diagnosis of idiopathic pulmonary hemosiderosis or a healed vasculitis such as granulomatosis with polyangiitis is entertained. While PVOD may be suggested if hemosiderosis and one or more sclerosed venules are identified in a biopsy specimen, this is not diagnostic because intimal sclerosis can be a normal consequence of aging. The presence of an occasional sclerosed pulmonary vein is not sufficient for diagnosis and must be interpreted in conjunction with clinical and radiographic features. (See  <a class="medical medical_review" href="/d/html/4318.html" rel="external">"Idiopathic pulmonary hemosiderosis"</a>.)</p><p>In our experience, autopsy or explanted lungs findings usually reveal components of mixed precapillary pulmonary hypertension  (<a class="graphic graphic_picture graphicRef64141" href="/d/graphic/64141.html" rel="external">picture 3</a>) and PVOD (ie, post capillary pulmonary hypertension) in various proportions suggesting that both forms of pulmonary hypertension may coexist and are not necessarily mutually exclusive [<a href="#rid135">135</a>]. Details regarding the pathology of arterial hypertension are described separately. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Idiopathic and heritable'</a>.)</p><p class="headingAnchor" id="H3348737935"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a>.)</p><p class="headingAnchor" id="H6670311"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) is a rare condition that represents a small subgroup of adult patients with pulmonary hypertension  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The true incidence of PVOD is unknown. However, the annual incidence is estimated to be 0.1 to 0.2 cases per million persons in the general population. It is more common in children and young adults but affects males and females equally. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Most cases of PVOD are idiopathic. The pathogenesis is unknown and likely multifactorial. Genetic mutations in the eukaryotic translation initiation factor 2-alpha kinase (<em>EIF2AK4</em>) gene have been described in the familial form of PVOD. In addition, several risk factors have been reported, including chemotherapeutic agents, hematopoietic stem cell transplantation, and autoimmune disorders. (See <a class="local">'Pathogenesis and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – We believe that a clinical diagnosis of PVOD can be made in most patients following an integrated assessment for pulmonary hypertension using a constellation of clinical, CT (usually contrast-enhanced)  (<a class="graphic graphic_diagnosticimage graphicRef105805" href="/d/graphic/105805.html" rel="external">image 4</a>), physiologic, and hemodynamic findings  (<a class="graphic graphic_table graphicRef105806" href="/d/graphic/105806.html" rel="external">table 3</a>). A clinical diagnosis of PVOD is typically made in those who have hemodynamic findings of pulmonary arterial hypertension (PAH; especially severe PAH) and the CT findings of venous congestion (eg, septal thickening, diffuse ground glass opacities and lymphadenopathy  (<a class="graphic graphic_diagnosticimage graphicRef71206" href="/d/graphic/71206.html" rel="external">image 5</a>)). (See <a class="local">'Evaluation and approach to clinical diagnosis'</a> above and <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical features</strong> – Most patients have nonspecific signs and symptoms of pulmonary hypertension. (See <a class="local">'Clinical manifestations of pulmonary hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Right heart catheterization and echocardiography</strong> – In most patients with PVOD, right heart catheterization findings are similar to those in patients with other forms of PAH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>); the mean pulmonary artery pressure is &gt;20 mmHg while the pulmonary artery wedge pressure is typically normal (≤15 mmHg) and pulmonary vascular resistance ≥3 Wood Units  (<a class="graphic graphic_table graphicRef70326" href="/d/graphic/70326.html" rel="external">table 4</a>). In keeping with these findings, echocardiographic evidence of left-sided heart disease is absent. (See <a class="local">'Overview'</a> above and <a class="local">'Right heart catheterization'</a> above and <a class="local">'Echocardiography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chest CT</strong> – Additional CT findings include multiple small nodules, pleural and pericardial effusions, alveolar consolidation, and normal-sized left atrium and major pulmonary veins. Ventilation perfusion scans are of limited diagnostic value because they are often normal or lead to misdiagnosis. (See <a class="local">'Overview'</a> above and <a class="local">'Venous congestion on chest imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary function</strong> – A severely low single breath diffusing capacity for carbon monoxide (DLCO; &lt;55 percent predicted) and severe hypoxemia (&lt;65 mmHg) are suggestive of PVOD but are considered by most experts as nonspecific. (See <a class="local">'Overview'</a> above and <a class="local">'Low diffusing capacity and poor oxygenation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Family history</strong> – A family history of PVOD and mutations in the <em>EIF2AK4</em> gene are strongly supportive of a diagnosis of PVOD, although rarely present. Similarly, the development of acute pulmonary edema on vasoreactivity testing or during the administration of PH-specific advanced therapy is also highly suggestive of PVOD. (See <a class="local">'Family history or EIF2AK4 mutation'</a> above and <a class="local">'Pulmonary edema from pulmonary vasodilators'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic delay</strong> – Delays in the diagnosis of PVOD are common since the condition is rare, the presentation is nonspecific, and not every patient presents with classic features. Thus, the diagnosis is sometimes only made retrospectively at autopsy or on explanted tissue. Rarely is PVOD found incidentally on lung biopsy material performed during the evaluation of interstitial lung disease. (See <a class="local">'Diagnostic delay'</a> above and <a class="local">'Lung biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – The pathologic hallmark of PVOD is extensive and diffuse occlusion of the pulmonary veins due to smooth muscle hypertrophy and collagen matrix deposition (ie, fibrous tissue)  (<a class="graphic graphic_picture graphicRef66071" href="/d/graphic/66071.html" rel="external">picture 1</a>). Additional pathologic features include arterialization of pulmonary veins, engorged and tortuous alveolar capillaries similar to those seen in PCH, dilated lymphatics, and hemosiderin-laden macrophages. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="headingAnchor" id="H3805248099"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Clardy, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33:189.</a></li><li><a class="nounderline abstract_t">Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87:220.</a></li><li><a class="nounderline abstract_t">O'Callaghan DS, Dorfmuller P, Jaïs X, et al. Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med 2011; 40:e65.</a></li><li><a class="nounderline abstract_t">Brown CH, Harrison CV. Pulmonary veno-occlusive disease. Lancet 1966; 2:61.</a></li><li><a class="nounderline abstract_t">Heath D, Segel N, Bishop J. Pulmonary veno-occlusive disease. Circulation 1966; 34:242.</a></li><li><a class="nounderline abstract_t">Weisser K, Wyler F, Gloor F. Pulmonary veno-occlusive disease. Arch Dis Child 1967; 42:322.</a></li><li><a class="nounderline abstract_t">Rosenthal A, Vawter G, Wagenvoort CA. Intrapulmonary veno-occlusive disease. Am J Cardiol 1973; 31:78.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Palazzini M, Manes A. Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension. Eur Respir Rev 2009; 18:177.</a></li><li><a class="nounderline abstract_t">Balke L, Both M, Winkler C, et al. Scintigraphy Leading to the Misdiagnosis of Chronic Thromboembolic Disease in a Patient With Pulmonary Veno-Occlusive Disease. Circulation 2016; 133:1627.</a></li><li><a class="nounderline abstract_t">Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80:1198.</a></li><li><a class="nounderline abstract_t">Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80:1207.</a></li><li><a class="nounderline abstract_t">Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980; 77:614.</a></li><li><a class="nounderline abstract_t">Kinare SG, Deshpande J. Primary pulmonary hypertension in India (autopsy study of 26 cases). Indian Heart J 1987; 39:9.</a></li><li><a class="nounderline abstract_t">Burke AP, Farb A, Virmani R. The pathology of primary pulmonary hypertension. Mod Pathol 1991; 4:269.</a></li><li class="breakAll">Pietra GG. The pathology of primary pulmonary hypertension. In: Primary pulmonary hypertension: lung biology in health and disease, Rubin LJ, Rich S (Eds), Marcel Dekker, Inc, New York 1997. p.19.</li><li><a class="nounderline abstract_t">Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60:16.</a></li><li><a class="nounderline abstract_t">Wagenvoort, CA, Wagenvoort, N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42:1163.</a></li><li><a class="nounderline abstract_t">Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111.</a></li><li><a class="nounderline abstract_t">Montani D, Lau EM, Descatha A, et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J 2015; 46:1721.</a></li><li><a class="nounderline abstract_t">Veeraraghavan S, Koss MN, Sharma OP. Pulmonary veno-occlusive disease. Curr Opin Pulm Med 1999; 5:310.</a></li><li><a class="nounderline abstract_t">Wagenvoort CA. Pulmonary veno-occlusive disease. Entity or syndrome? Chest 1976; 69:82.</a></li><li><a class="nounderline abstract_t">Thadani U, Burrow C, Whitaker W, Heath D. Pulmonary veno-occlusive disease. Q J Med 1975; 44:133.</a></li><li><a class="nounderline abstract_t">Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant 2008; 41:677.</a></li><li><a class="nounderline abstract_t">Davies P, Reid L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum Pathol 1982; 13:911.</a></li><li><a class="nounderline abstract_t">Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977; 32:763.</a></li><li><a class="nounderline abstract_t">Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65.</a></li><li><a class="nounderline abstract_t">Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation 2017; 136:2022.</a></li><li><a class="nounderline abstract_t">Montani D, Girerd B, Jaïs X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017; 5:125.</a></li><li><a class="nounderline abstract_t">Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 2014; 145:231.</a></li><li><a class="nounderline abstract_t">Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003; 167:889.</a></li><li><a class="nounderline abstract_t">Takemori W, Yamamura K, Tomita Y, et al. Pediatric pulmonary veno-occlusive disease associated with a novel BMPR2 variant. Pediatr Pulmonol 2022; 57:1366.</a></li><li><a class="nounderline abstract_t">Perros F, Cohen-Kaminsky S, Gambaryan N, et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2013; 187:189.</a></li><li><a class="nounderline abstract_t">Doll DC, Yarbro JW. Vascular toxicity associated with chemotherapy and hormonotherapy. Curr Opin Oncol 1994; 6:345.</a></li><li><a class="nounderline abstract_t">Gagnadoux F, Capron F, Lebeau B. Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 2002; 36:213.</a></li><li><a class="nounderline abstract_t">Perros F, Günther S, Ranchoux B, et al. Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. Circulation 2015; 132:834.</a></li><li><a class="nounderline abstract_t">Lombard CM, Churg A, Winokur S. Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 1987; 92:871.</a></li><li><a class="nounderline abstract_t">Ranchoux B, Günther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015; 185:356.</a></li><li><a class="nounderline abstract_t">Certain MC, Chaumais MC, Jaïs X, et al. Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest 2021; 159:1197.</a></li><li><a class="nounderline abstract_t">Liu, L, Sackler, JP. A case of pulmonary veno-occlusive disease: etiological and therapeutic appraisal. Angiology 1973; 23:299.</a></li><li><a class="nounderline abstract_t">Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609.</a></li><li><a class="nounderline abstract_t">Kumana CR, Ng M, Lin HJ, et al. Herbal tea induced hepatic veno-occlusive disease: quantification of toxic alkaloid exposure in adults. Gut 1985; 26:101.</a></li><li><a class="nounderline abstract_t">Tandon BN, Tandon HD, Tandon RK, et al. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2:271.</a></li><li><a class="nounderline abstract_t">Williams LM, Fussell S, Veith RW, et al. Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest 1996; 109:1388.</a></li><li><a class="nounderline abstract_t">Kramer MR, Estenne M, Berkman N, et al. Radiation-induced pulmonary veno-occlusive disease. Chest 1993; 104:1282.</a></li><li><a class="nounderline abstract_t">Gutman JA, Allen CT, Madtes DK, et al. Pulmonary veno-occlusive disease following reduced-intensity cord blood transplantation. Bone Marrow Transplant 2008; 42:559.</a></li><li><a class="nounderline abstract_t">Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989; 47:989.</a></li><li><a class="nounderline abstract_t">Gazourian L, Spring L, Meserve E, et al. Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. Biol Blood Marrow Transplant 2017; 23:1767.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-1983. A 67-year-old woman with pulmonary hypertension. N Engl J Med 1983; 308:823.</a></li><li><a class="nounderline abstract_t">Hussein A, Trowitzsch E, Brockmann M. Pulmonary veno-occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent. Klin Padiatr 1999; 211:92.</a></li><li><a class="nounderline abstract_t">Kishida Y, Kanai Y, Kuramochi S, Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993; 20:2161.</a></li><li><a class="nounderline abstract_t">Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134:809.</a></li><li><a class="nounderline abstract_t">Hamada K, Teramoto S, Narita N, et al. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15:421.</a></li><li><a class="nounderline abstract_t">Morassut PA, Walley VM, Smith CD. Pulmonary veno-occlusive disease and the CREST variant of scleroderma. Can J Cardiol 1992; 8:1055.</a></li><li><a class="nounderline abstract_t">Saito A, Takizawa H, Ito K, et al. A case of pulmonary veno-occlusive disease associated with systemic sclerosis. Respirology 2003; 8:383.</a></li><li><a class="nounderline abstract_t">Zhang L, Visscher D, Rihal C, Aubry MC. Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease. Rheumatol Int 2007; 27:1163.</a></li><li><a class="nounderline abstract_t">Johnson SR, Patsios D, Hwang DM, Granton JT. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006; 33:2347.</a></li><li><a class="nounderline abstract_t">Crissman JD, Koss M, Carson RP. Pulmonary veno-occlusive disease secondary to granulomatous venulitis. Am J Surg Pathol 1980; 4:93.</a></li><li><a class="nounderline abstract_t">Liang MH, Stern S, Fortin PR, et al. Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: a new syndrome presenting with facial swelling and pericardial tamponade. Arthritis Rheum 1991; 34:228.</a></li><li><a class="nounderline abstract_t">Dwyer N, Smith R, Challis D, et al. Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture. Eur Respir J 2009; 33:666.</a></li><li><a class="nounderline abstract_t">Günther S, Jaïs X, Maitre S, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012; 64:2995.</a></li><li><a class="nounderline abstract_t">Hasleton PS, Ironside JW, Whittaker JS, et al. Pulmonary veno-occlusive disease. A report of four cases. Histopathology 1986; 10:933.</a></li><li><a class="nounderline abstract_t">Kokturk N, Demir N, Demircan S, et al. Pulmonary veno-occlusive disease in a patient with a history of Hashimoto's thyroiditis. Indian J Chest Dis Allied Sci 2005; 47:289.</a></li><li><a class="nounderline abstract_t">Naniwa T, Takeda Y. Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren's syndrome following immunosuppressive therapy. Mod Rheumatol 2011; 21:637.</a></li><li><a class="nounderline abstract_t">Devereux G, Evans MJ, Kerr KM, Legge JS. Pulmonary veno-occlusive disease complicating Felty's syndrome. Respir Med 1998; 92:1089.</a></li><li><a class="nounderline abstract_t">Kay D, Kadri F, Fitzpatrick G, et al. Anti-synthetase syndrome-associated pulmonary veno-occlusive disease. Pulm Circ 2020; 10:2045894020935289.</a></li><li><a class="nounderline abstract_t">Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34:371.</a></li><li><a class="nounderline abstract_t">Connolly MJ, Abdullah S, Ridout DA, et al. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Rheumatology (Oxford) 2017; 56:2197.</a></li><li><a class="nounderline abstract_t">Höra, J . Zur Histologie der klinischen "primaren Pulmonalsklerose". Frankfurt Z Pathol 1934; 47:100.</a></li><li><a class="nounderline abstract_t">Pulmonary veno-occlusive disease. Br Med J 1972; 3:369.</a></li><li><a class="nounderline abstract_t">STOVIN PG, MITCHINSON MJ. PULMONARY HYPERTENSION DUE TO OBSTRUCTION OF THE INTRAPULMONARY VEINS. Thorax 1965; 20:106.</a></li><li><a class="nounderline abstract_t">McDonnell PJ, Summer WR, Hutchins GM. Pulmonary veno-occlusive disease. Morphological changes suggesting a viral cause. JAMA 1981; 246:667.</a></li><li><a class="nounderline abstract_t">Ruchelli ED, Nojadera G, Rutstein RM, Rudy B. Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med 1994; 118:664.</a></li><li><a class="nounderline abstract_t">Escamilla R, Hermant C, Berjaud J, et al. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995; 8:1982.</a></li><li><a class="nounderline abstract_t">A case of veno-occlusive disease. Demonstrated at the Royal Postgraduate Medical School. Br Med J 1968; 1:818.</a></li><li><a class="nounderline abstract_t">Townend JN, Roberts DH, Jones EL, Davies MK. Fatal pulmonary venoocclusive disease after use of oral contraceptives. Am Heart J 1992; 124:1643.</a></li><li><a class="nounderline abstract_t">Tsou E, Waldhorn RE, Kerwin DM, et al. Pulmonary venoocclusive disease in pregnancy. Obstet Gynecol 1984; 64:281.</a></li><li><a class="nounderline abstract_t">Urisman A, Leard LE, Nathan M, et al. Rapidly progressive pulmonary venoocclusive disease in young women taking oral contraceptives. J Heart Lung Transplant 2012; 31:1031.</a></li><li><a class="nounderline abstract_t">Tachibana T, Nakayama N, Matsumura A, et al. Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. Intern Med 2017; 56:2487.</a></li><li><a class="nounderline abstract_t">Carrington CB, Liebow AA. Pulmonary veno-occlusive disease. Hum Pathol 1970; 1:322.</a></li><li><a class="nounderline abstract_t">D'Souza M, Vergales J, Jayakumar KA. Hypoplastic left heart syndrome and pulmonary veno-occlusive disease in an infant. Pediatr Cardiol 2013; 34:1949.</a></li><li><a class="nounderline abstract_t">Murakami T, Horigome H, Yamaki S, et al. Pulmonary veno-occlusive disease associated with partial anomalous pulmonary venous connection. Pediatr Int 2003; 45:747.</a></li><li><a class="nounderline abstract_t">Shrivastava S, Moller JH, Edwards JE. Congenital unilateral pulmonary venous atresia with pulmonary veno-occlusive disease in contralateral lung: an unusual association. Pediatr Cardiol 1986; 7:213.</a></li><li><a class="nounderline abstract_t">Güttinger E, Vrugt B, Speich R, et al. Reactive Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-Occlusive Disease in a Patient with Repaired Scimitar Syndrome. Case Rep Cardiol 2016; 2016:9384126.</a></li><li><a class="nounderline abstract_t">Montani D, O'Callaghan DS, Savale L, et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010; 104 Suppl 1:S23.</a></li><li><a class="nounderline abstract_t">Montani D, Kemp K, Dorfmuller P, et al. Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med 2009; 30:411.</a></li><li><a class="nounderline abstract_t">Dai Z, Matsui Y. Pulmonary veno-occlusive disease: an 80-year-old mystery. Respiration 2014; 88:148.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Lantuéjoul S, Sheppard MN, Corrin B, et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30:850.</a></li><li><a class="nounderline abstract_t">Holcomb BW Jr, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118:1671.</a></li><li><a class="nounderline abstract_t">Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183:65.</a></li><li><a class="nounderline abstract_t">Jones RM, Dawson A, Jenkins GH, et al. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009; 34:517.</a></li><li><a class="nounderline abstract_t">Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964.</a></li><li><a class="nounderline abstract_t">Pérez Núñez M, Alonso Charterina S, Pérez-Olivares C, et al. Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Veno-Occlusive Disease: Certainties and Uncertainties. Diagnostics (Basel) 2021; 11.</a></li><li><a class="nounderline abstract_t">Frazier AA, Franks TJ, Mohammed TL, et al. From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 2007; 27:867.</a></li><li><a class="nounderline abstract_t">Leinonen H, Pohjola-Sintonen S, Krogerus L. Pulmonary veno-occlusive disease. Acta Med Scand 1987; 221:307.</a></li><li><a class="nounderline abstract_t">Elliott CG, Colby TV, Hill T, Crapo RO. Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. Respiration 1988; 53:262.</a></li><li><a class="nounderline abstract_t">Scheibel RL, Dedeker KL, Gleason DF, et al. Radiographic and angiographic characteristics of pulmonary veno-occlusive disease. Radiology 1972; 103:47.</a></li><li><a class="nounderline abstract_t">Swensen SJ, Tashjian JH, Myers JL, et al. Pulmonary venoocclusive disease: CT findings in eight patients. AJR Am J Roentgenol 1996; 167:937.</a></li><li><a class="nounderline abstract_t">Wiener-Kronish JP, Goldstein R, Matthay RA, et al. Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension. Chest 1987; 92:967.</a></li><li><a class="nounderline abstract_t">Resten A, Maître S, Humbert M, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002; 222:782.</a></li><li><a class="nounderline abstract_t">Cassart M, Gevenois PA, Kramer M, et al. Pulmonary venoocclusive disease: CT findings before and after single-lung transplantation. AJR Am J Roentgenol 1993; 160:759.</a></li><li><a class="nounderline abstract_t">Worthy SA, Müller NL, Hartman TE, et al. Mosaic attenuation pattern on thin-section CT scans of the lung: differentiation among infiltrative lung, airway, and vascular diseases as a cause. Radiology 1997; 205:465.</a></li><li><a class="nounderline abstract_t">Miura A, Akagi S, Nakamura K, et al. Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmonary capillary hemangiomatosis. Cardiovasc Pathol 2013; 22:287.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 48-1993. A 27-year-old woman with mediastinal lymphadenopathy and relentless cor pulmonale. N Engl J Med 1993; 329:1720.</a></li><li><a class="nounderline abstract_t">Dufour B, Maître S, Humbert M, et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171:1321.</a></li><li><a class="nounderline abstract_t">Thomas de Montpréville V, Dulmet E, Fadel E, Dartevelle P. Lymph node pathology in pulmonary veno-occlusive disease and pulmonary capillary heamangiomatosis. Virchows Arch 2008; 453:171.</a></li><li><a class="nounderline abstract_t">Seferian A, Helal B, Jaïs X, et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012; 40:75.</a></li><li><a class="nounderline abstract_t">Rich S, Pietra GG, Kieras K, et al. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 1986; 105:499.</a></li><li><a class="nounderline abstract_t">Bailey CL, Channick RN, Auger WR, et al. "High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med 2000; 162:1974.</a></li><li><a class="nounderline abstract_t">Pérez-Olivares C, Segura de la Cal T, Flox-Camacho Á, et al. The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. Eur Respir J 2021; 57.</a></li><li><a class="nounderline abstract_t">Laveneziana P, Montani D, Dorfmüller P, et al. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. Eur Respir J 2014; 44:1069.</a></li><li><a class="nounderline abstract_t">Weed HG. Pulmonary "capillary" wedge pressure not the pressure in the pulmonary capillaries. Chest 1991; 100:1138.</a></li><li><a class="nounderline abstract_t">Rambihar VS, Fallen EL, Cairns JA. Pulmonary veno-occlusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings. Can Med Assoc J 1979; 120:1519.</a></li><li><a class="nounderline abstract_t">Chawla SK, Kittle CF, Faber LP, Jensik RJ. Pulmonary venoocclusive disease. Ann Thorac Surg 1976; 22:249.</a></li><li><a class="nounderline abstract_t">Rapidly progressive dyspnea in a teenage boy. Clinical pathological conference. JAMA 1973; 223:1243.</a></li><li><a class="nounderline abstract_t">Masters K, Bennett S. Pulmonary veno-occlusive disease: an uncommon cause of pulmonary hypertension. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113:237.</a></li><li><a class="nounderline abstract_t">Rabiller A, Jaïs X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006; 27:108.</a></li><li><a class="nounderline abstract_t">Matthews AW, Buchanan R. A case of pulmonary veno-occlusive disease and a new bronchoscopic sign. Respir Med 1990; 84:503.</a></li><li><a class="nounderline abstract_t">Waldhorn RE, Tsou E, Smith FP, Kerwin DM. Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984; 12:394.</a></li><li><a class="nounderline abstract_t">Sanderson JE, Spiro SG, Hendry AT, Turner-Warwick M. A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine. Thorax 1977; 32:140.</a></li><li><a class="nounderline abstract_t">De Vries TW, Weening JJ, Roorda RJ. Pulmonary veno-occlusive disease: a case report and a review of therapeutic possibilities. Eur Respir J 1991; 4:1029.</a></li><li class="breakAll">Rubin E, Farber JL. The respiratory system. In: Pathology, 2nd ed, Rubin E, Farber JL (Eds), J.B. Lippincott, Philadelphia 1994. p.557.</li><li><a class="nounderline abstract_t">Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974; 364:69.</a></li><li><a class="nounderline abstract_t">Stewart S, Rassl D. Advances in the understanding and classification of pulmonary hypertension. Histopathology 2009; 54:104.</a></li><li><a class="nounderline abstract_t">Cortese DA. Pulmonary function in mitral stenosis. Mayo Clin Proc 1978; 53:321.</a></li><li><a class="nounderline abstract_t">Wagenvoort CA, Wagenvoort N, Takahashi T. Pulmonary veno-occlusive disease: involvement of pulmonary arteries and review of the literature. Hum Pathol 1985; 16:1033.</a></li><li><a class="nounderline abstract_t">Almagro P, Julià J, Sanjaume M, et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 2002; 81:417.</a></li><li><a class="nounderline abstract_t">Ito K, Ichiki T, Ohi K, et al. Pulmonary capillary hemangiomatosis with severe pulmonary hypertension. Circ J 2003; 67:793.</a></li><li><a class="nounderline abstract_t">Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22:385.</a></li><li><a class="nounderline abstract_t">Oviedo A, Abramson LP, Worthington R, et al. Congenital pulmonary capillary hemangiomatosis: Report of two cases and review of the literature. Pediatr Pulmonol 2003; 36:253.</a></li><li><a class="nounderline abstract_t">Matsukuma S, Sato K. Pulmonary capillary haemangiomatosis-like lesions in severely congested lungs. Histopathology 2011; 59:876.</a></li><li><a class="nounderline abstract_t">Glassroth J, Woodford DW, Carrington CB, Gaensler EA. Pulmonary veno-occlusive disease in the middle-aged. Respiration 1985; 47:309.</a></li><li><a class="nounderline abstract_t">Nossent EJ, Antigny F, Montani D, et al. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. J Heart Lung Transplant 2018; 37:647.</a></li></ol></div><div id="topicVersionRevision">Topic 8269 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118230" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626305" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21211937" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4161019" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5969356" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6025375" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4682413" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intrapulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956140" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27142608" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Scintigraphy Leading to the Misdiagnosis of Chronic Thromboembolic Disease in a Patient With Pulmonary Veno-Occlusive Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2805258" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2805259" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7363679" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lung biopsy specimens in the evaluation of pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3505506" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Primary pulmonary hypertension in India (autopsy study of 26 cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2047387" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The pathology of primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2047387" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The pathology of primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965821" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary pulmonary hypertension: a histopathologic study of 80 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988890" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26541523" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10461536" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244294" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pulmonary veno-occlusive disease. Entity or syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1153689" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18223697" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7129408" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulmonary veno-occlusive disease in siblings: case reports and morphometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/601742" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Familial pulmonary veno-occlusive disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24292273" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972005" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28087362" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24135949" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : EIF2AK4 mutations in pulmonary capillary hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12446270" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35229499" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pediatric pulmonary veno-occlusive disease associated with a novel BMPR2 variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23220918" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7803535" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vascular toxicity associated with chemotherapy and hormonotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955658" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26130118" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3665603" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulmonary veno-occlusive disease following therapy for malignant neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497573" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Chemotherapy-induced pulmonary hypertension: role of alkylating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979348" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A case of pulmonary veno-occlusive disease: etiological and therapeutic appraisal</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8692238" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965360" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Herbal tea induced hepatic veno-occlusive disease: quantification of toxic alkaloid exposure in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/59849" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : An epidemic of veno-occlusive disease of liver in central India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625695" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404211" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Radiation-induced pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18641679" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pulmonary veno-occlusive disease following reduced-intensity cord blood transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2660361" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary venoocclusive disease following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28668489" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6835274" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-1983. A 67-year-old woman with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10407819" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pulmonary veno-occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8014950" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767134" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sarcoidosis simulating pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706515" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1288837" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulmonary veno-occlusive disease and the CREST variant of scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14528885" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A case of pulmonary veno-occlusive disease associated with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17520258" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16981286" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7361999" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulmonary veno-occlusive disease secondary to granulomatous venulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994922" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: a new syndrome presenting with facial swelling and pericardial tamponade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19251802" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22549387" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3781491" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pulmonary veno-occlusive disease. A report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16255401" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pulmonary veno-occlusive disease in a patient with a history of Hashimoto's thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21394665" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren's syndrome following immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9893784" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulmonary veno-occlusive disease complicating Felty's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32655855" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Anti-synthetase syndrome-associated pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282344" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029203" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Zur Histologie der klinischen "primaren Pulmonalsklerose"</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5070157" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14264634" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : PULMONARY HYPERTENSION DUE TO OBSTRUCTION OF THE INTRAPULMONARY VEINS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7253118" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pulmonary veno-occlusive disease. Morphological changes suggesting a viral cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8204018" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8620974" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4230518" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A case of veno-occlusive disease. Demonstrated at the Royal Postgraduate Medical School.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1462933" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Fatal pulmonary venoocclusive disease after use of oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6738961" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pulmonary venoocclusive disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22884388" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rapidly progressive pulmonary venoocclusive disease in young women taking oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28824072" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5521729" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22961346" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hypoplastic left heart syndrome and pulmonary veno-occlusive disease in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14651556" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pulmonary veno-occlusive disease associated with partial anomalous pulmonary venous connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3822868" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Congenital unilateral pulmonary venous atresia with pulmonary veno-occlusive disease in contralateral lung: an unusual association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069695" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Reactive Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-Occlusive Disease in a Patient with Repaired Scimitar Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456932" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pulmonary veno-occlusive disease: recent progress and current challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19634080" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853728" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pulmonary veno-occlusive disease: an 80-year-old mystery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16819327" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115457" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pulmonary veno-occlusive disease: a case series and new observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208112" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648528" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069841" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33477983" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Veno-Occlusive Disease: Certainties and Uncertainties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17495297" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2954433" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3175350" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4259397" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Radiographic and angiographic characteristics of pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8819387" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pulmonary venoocclusive disease: CT findings in eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3677841" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867801" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8456659" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pulmonary venoocclusive disease: CT findings before and after single-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356630" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Mosaic attenuation pattern on thin-section CT scans of the lung: differentiation among infiltrative lung, airway, and vascular diseases as a cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312620" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmonary capillary hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232462" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 48-1993. A 27-year-old woman with mediastinal lymphadenopathy and relentless cor pulmonale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9798872" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18551306" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Lymph node pathology in pulmonary veno-occlusive disease and pulmonary capillary heamangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22088969" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Ventilation/perfusion lung scan in pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752755" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069842" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : "High probability" perfusion lung scans in pulmonary venoocclusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33653804" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25142489" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1914574" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Pulmonary "capillary" wedge pressure not the pressure in the pulmonary capillaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/455208" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Pulmonary veno-occlusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/962409" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Pulmonary venoocclusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4265571" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Rapidly progressive dyspnea in a teenage boy. Clinical pathological conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378546" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pulmonary veno-occlusive disease: an uncommon cause of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440597" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387942" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Occult alveolar haemorrhage in pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2274690" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A case of pulmonary veno-occlusive disease and a new bronchoscopic sign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6548790" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/867325" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1783079" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pulmonary veno-occlusive disease: a case report and a review of therapeutic possibilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1783079" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Pulmonary veno-occlusive disease: a case report and a review of therapeutic possibilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4217029" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The pathology of pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187180" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Advances in the understanding and classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/347185" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pulmonary function in mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4043952" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Pulmonary veno-occlusive disease: involvement of pulmonary arteries and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441898" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12939557" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Pulmonary capillary hemangiomatosis with severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590835" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910588" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Congenital pulmonary capillary hemangiomatosis: Report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092399" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Pulmonary capillary haemangiomatosis-like lesions in severely congested lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4012048" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Pulmonary veno-occlusive disease in the middle-aged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108819" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
